VistaGen Therapeutics Inc (VTGN)

[Fress]

The MM blocking crew trying too hard...watch what happens next!


Institutional ownership getting close to 60% in 2 months in 2021 with the most current 13Gs up from 7% late last year.


SAD Social Anxiety disorder Phase 3 Fast tracked first ever for SAD by the FDA.


Multiple phase 2's.


105 million in cash.


VTGN next generation Depression Anxiety meds.


close to 50% of adults polled say they have depression & or anxiety.



VTGN 2021 Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A


VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 1.7 billion market cap very early clinical trials. 170 million cash
$MMEDF 1.1 billion market cap. Phase 2
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 333 million market cap Phase 3 ready. (nasdaq)
105 million in cash


$VTGN